Oculis Holding AG

As of October 31, 2025, Oculis Holding AG's technical trend is neutral with mixed signals, showing a recent underperformance of -9.27% compared to the S&P 500's 0.71% over the past week, but a strong outperformance of 10.8% versus 1.92% over the past month.

As of October 31, 2025, Oculis Holding AG's technical trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, while it has underperformed the S&P 500 recently but outperformed it over the past three years.

As of October 24, 2025, Oculis Holding AG's technical trend is neutral with mixed signals, showing a mildly bullish weekly MACD and a mildly bearish monthly MACD, while outperforming the S&P 500 with a year-to-date return of 25.0% compared to 15.47%.

As of October 24, 2025, Oculis Holding AG's technical trend is neutral, showing mixed signals with a mildly bullish weekly MACD and a bearish daily moving average, while outperforming the S&P 500 year-to-date with a 25.0% return compared to 15.47%.

As of October 24, 2025, Oculis Holding AG's technical trend has shifted to sideways, with mixed signals from indicators like MACD and OBV, while it has outperformed the S&P 500 year-to-date and over the past year.

As of September 10, 2025, Oculis Holding AG's trend is mildly bearish, with mixed signals from technical indicators, having returned 45.61% over the past year but underperforming in the last month with a -3.65% return compared to the S&P 500's 2.33%.

As of June 17, 2025, Oculis Holding AG's technical trend has shifted to bullish, supported by strong indicators like a bullish MACD, Bollinger Bands, and moving averages across multiple time frames.

Oculis Holding AG is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $37 million and a market cap of $1.19 billion. Key financial metrics include a negative P/E ratio, a 0% dividend yield, and a return on equity of -43.40%.

As of Jun 18, Oculis Holding AG has a market capitalization of 1,193.22 million and reported net sales of 0.00 million with a net profit of -115.95 million for the latest four quarters. Shareholder's funds are 80.97 million and total assets amount to 132.80 million.